House Dust Mite Tablets Now Officially Accepted as Treatment in GINA: What Is the Evidence and What ’s Next?

AbstractPurpose of ReviewThis review analyzes the growing evidence regarding the standardized quality house dust mite (SQ-HDM) sublingual immunotherapy (SLIT) tablets as a valuable therapeutic option in asthma, as recently included in the treatment algorithm of the Global Initiative for Asthma (GINA) as an add-on treatment for adult patients with allergic asthma not well controlled with inhaled corticosteroids (ICS).Recent FindingsEvidence from well-designed randomized placebo-controlled clinical trials shows that the SQ-HDM SLIT tablet is effective vs. placebo in reducing both asthma symptoms and the need for ICS, as well as the risk of experiencing a moderate/severe asthma exacerbation following ICS reduction, besides having a very good safety profile and tolerability. However, some unmet needs remain that need to be resolved.SummaryThe approval of the SQ-HDM SLIT tablet by regulatory authorities in Europe and the United States and its inclusion in the treatment recommendations in GINA open an opportunity window to enhance the range of management options in some patients with asthma by using an ethology-based treatment. Further studies are needed to facilitate the more complete evaluation of the therapeutic effect of this and other related products.
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research